Board approved audited FY26 results with 13.48% revenue growth and 20.35% PAT increase year-on-year.
Statutory auditors issued unmodified opinion on financial statements for year ended March 31, 2026.
Pharma packs segment showed exceptional 208.96% volume growth while overall sales volumes grew 11.39%.
Company consolidated Hyderabad manufacturing units and expects to cross ₹1000 crore turnover in FY27.